21/11/2017 - 06:38

MGC Pharma signs epilepsy marijuana treatment deal

21/11/2017 - 06:38

Bookmark

Save articles for future reference.

MGC Pharmaceuticals have signed a distribution deal with local pharmaceutical distributor HL Pharma to launch its cannabis-based epilepsy treatment, CannEpil, in Australia. MGC wants to target the more than 70,000 Australian sufferers of the condition and sees it as a significant additional revenue stream ahead. The company says it now has a pathway to deliver the drug to patients from 2018.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options